{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:59:28Z","timestamp":1793282368885,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtho.2024.12.028","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T03:01:16Z","timestamp":1735786876000},"page":"799-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-6839","authenticated-orcid":false,"given":"Afshin","family":"Dowlati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Fen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tazbirkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana Gabriela","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"van Marcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilpa","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeen","family":"Mekan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiama N.","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.12.028_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib3","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/cncr.35281","article-title":"The changing landscape of small cell lung cancer","volume":"130","author":"Cittolin-Santos","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2024.12.028_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.5187","article-title":"Moving beyond limited and extensive staging of small cell lung cancer","volume":"5","author":"West","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.5335","article-title":"Association of chemoradiotherapy with outcomes among patients with stage I to II vs stage III small cell lung cancer: secondary analysis of a randomized clinical trial","volume":"5","author":"Salem","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib6","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.23.01435","article-title":"Systemic therapy for small-cell lung cancer: ASCO-Ontario health (Cancer Care Ontario) guideline","volume":"41","author":"Khurshid","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib7","unstructured":"Referenced With Permission From the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Small Cell Lung Cancer. V.3.2024. \u00a9 National Comprehensive Cancer Network, Inc; 2024. All rights reserved. Accessed June 26, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Small Cell Lung Cancer. V.3.2024. \u00a9 National Comprehensive Cancer Network, Inc; 2024. All rights reserved. Accessed June 26, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.jtho.2024.12.028_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: first-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib9","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1007\/s12325-021-01909-1","article-title":"Advances in treatment of recurrent small cell lung cancer (SCLC): insights for optimizing patient outcomes from an expert roundtable discussion","volume":"38","author":"Das","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtho.2024.12.028_bib10","series-title":"Prescribing Information","year":"2019"},{"key":"10.1016\/j.jtho.2024.12.028_bib11","series-title":"Summary of Product Characteristics","year":"2023"},{"key":"10.1016\/j.jtho.2024.12.028_bib12","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib14","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"RESILIENT part 2: a randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib15","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib16","series-title":"Prescribing Information","year":"2023"},{"key":"10.1016\/j.jtho.2024.12.028_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (Atlantis): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2024.12.028_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8613","article-title":"A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator\u2019s choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)","volume":"41","author":"Besse","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib20","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.028_bib21","series-title":"Prescribing Information","year":"2024"},{"key":"10.1016\/j.jtho.2024.12.028_bib22","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.028_bib23","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.12.028_bib24","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.028_bib25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.jtho.2024.12.028_bib26","series-title":"Prescribing Information","year":"2023"},{"key":"10.1016\/j.jtho.2024.12.028_bib27","series-title":"Summary of Product Characteristics","year":"2021"},{"key":"10.1016\/j.jtho.2024.12.028_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"10.1016\/j.jtho.2024.12.028_bib29","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.12.028_bib30","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib31","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab govitecan demonstrates efficacy across tumor trop-2 expression levels in patients with advanced urothelial cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.028_bib32","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2024.12.028_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ctrv.2010.05.004","article-title":"Second-line chemotherapy for small-cell lung cancer (SCLC)","volume":"37","author":"Kim","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2024.12.028_bib34","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.028_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cllc.2023.01.012","article-title":"Current and emerging treatment options for patients with relapsed small-cell lung carcinoma: a systematic literature review","volume":"24","author":"Bernab\u00e9-Caro","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.12.028_bib36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib38","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1535-7163.MCT-23-0524","article-title":"HPN328, a trispecific T cell-activating protein construct targeting DLL3-expressing solid tumors","volume":"23","author":"Molloy","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2024.12.028_bib39","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jtho.2024.09.033","article-title":"OA04.03 Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): interim analysis of IDeate-Lung01","volume":"19","author":"Rudin","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib40","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jtho.2024.09.036","article-title":"OA04.06 efficacy and safety of HS-20093 in extensive stage small cell lung cancer in a multicenter, phase 1 study (ARTEMIS-001)","volume":"19","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib41","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/j.jtho.2023.09.667","article-title":"P2.16-06 a phase 2 study of ifinatamab deruxtecan (I-DXd; DS-7300) in patients with previously treated ES-SCLC","volume":"18","author":"Rudin","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib42","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1200\/JCO.2023.41.16_suppl.3017","article-title":"ARTEMIS-001: phase 1 study of HS-20093, a B7-H3\u2013targeting antibody-drug conjugate, in patients with advanced solid tumor","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib43","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jtho.2024.09.035","article-title":"OA04.05 SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients (pts) with advanced small-cell lunch cancer (SCLC)","volume":"19","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02823","article-title":"Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304)","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib45","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.028_bib46","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib47","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib48","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.028_bib49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.jtho.2024.12.028_bib50","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T20:24:51Z","timestamp":1766780691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424025498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1556086424025498"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.028","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}